Biotech by P/E ratio
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Exelixis has the lowest figure of the 9 biotech ranked by P/E ratio, at 20.7, followed by Neurocrine Biosciences (24.2) and Halozyme Therapeutics (24.3). Figures as of 18 Nov 2026, 15:14 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 9
- Lowest
- Exelixis20.7
- Median
- 26.8
- Combined market value
- CHF 714.4B
- Countries
- 5
- Not ranked
- 15no P/E ratio on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | P/E ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | ExelixisEXEL · Health Care | 20.7 | CHF 14.2B | CHF 58.33 | 0.96% up | 63% up | ||
| 2 | Neurocrine BiosciencesNBIX · Health Care | 24.2 | CHF 13.9B | CHF 137.74 | 1.57% down | 20% up | ||
| 3 | Halozyme TherapeuticsHALO · Health Care | 24.3 | CHF 9.3B | CHF 81.96 | 1.26% up | 37% up | ||
| 4 | AmgenAMGN · Health Care | 26.1 | CHF 205.5B | CHF 379.92 | 1.64% down | 34% up | ||
| 5 | QiagenQGEN · Health Care | 26.8 | CHF 8.6B | CHF 41.89 | 0.18% down | 12% up | ||
| 6 | argenxARGX · Health Care | 33.3 | CHF 51B | CHF 810.61 | 1.43% up | 4% up | ||
| 7 | Krystal BiotechKRYS · Health Care | 42.0 | CHF 7.7B | CHF 260.96 | 3.63% up | 46% up | ||
| 8 | Bio-TechneTECH · Health Care | 66.7 | CHF 9.6B | CHF 61.32 | 0.10% up | 26% up | ||
| 9 | BiogenBIIB · Health Care | 108 | CHF 31.2B | CHF 211.11 | 0.20% down | 49% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8435 CHF). 15 companies have no P/E ratio on file and are not ranked here.
Questions and answers
Which biotech have the lowest P/E ratio?
Exelixis (20.7), Neurocrine Biosciences (24.2) and Halozyme Therapeutics (24.3) have the lowest P/E ratio of the 9 biotech ranked here as of 18 Nov 2026, 15:14 UTC.
How many biotech are in this ranking?
9 are ranked by P/E ratio. 15 more have no P/E ratio on file and are left out rather than ranked at zero.
What are these biotech worth together?
The 9 biotech ranked by P/E ratio have a combined market value of CHF 714.4B as of 18 Nov 2026, 15:14 UTC.
What does ranking by P/E ratio measure?
Share price divided by the last twelve months' earnings per share: how many years of today's profit the price pays for. A company making a loss has none.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by P/E ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=pe-ratio
Underlying data: Yahoo Finance; SEC EDGAR.